According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 4.04%, which means ...

DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first and only ...

AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

The “ Acute Myocardial Infarction Market Report ” by DelveInsight offers a robust analysis of market size, treatment ...

AstraZeneca, one of the largest companies in Britain, was the biggest loser in the FTSE 100 yesterday, slumping 6.8pc, or 707p, to 9667p. It was followed by rival GSK, which tumbled 5.7 per cent ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of products. Pharmaceutical giant AstraZeneca announced its fourth ...

In substance and timing, AstraZeneca's decision to cancel a planned expansion of its flu vaccine facility at Speke is a blow to the government's recent zeal for growth. Instead of injecting £450m ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry ...

Discover AstraZeneca's complete financial story with InvestingPro's comprehensive research report, featuring detailed analysis of the company's valuation, growth prospects, and competitive position.